Free fatty acids and type 2 diabetes mellitus

American Journal of Medicine

Volumn 115, Issue 8 SUPPL. 1, 2003, Pages 29-36

  Wyne, Kathleen L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ATORVASTATIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; RESISTIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

APOPTOSIS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; ENDOTHELIUM; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MICROALBUMINURIA; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PARTICLE SIZE; PRIORITY JOURNAL; RISK FACTOR; STROKE; SUDDEN DEATH; VASCULAR SMOOTH MUSCLE;

EID: 0347480400     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.004     Document Type: Conference Paper

References (77)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Boden G., Lebed B., Schatz M., et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes. 50:2001;1612-1617.
3. 1H-MRS study . Magn Reson Med. 45:2001;179-183.
4. McGarry J.D. Banting lecture 2001 dysregulation of fatty acid metabolism in the etiology of type 2 diabetes . Diabetes. 51:2002;7-18.
5. 1H-spectroscopic study in Zucker diabetic fatty rats . Diabetes. 52:2003;138-144.
6. Perseghin G., Ghosh S., Gerow K., Shulman G.I. Metabolic defects in lean nondiabetic offspring of NIDDM parents a cross-sectional study . Diabetes. 46:1997;1001-1009.
7. Blüher M., Kratzsch J., Paschke R. Plasma levels of tumor necrosis factor-α, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care. 24:2001;328-334.
8. Jouven X., Charles M.-A., Desnos M., Ducimetière P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation. 104:2001;756-761.
9. Carlsson M., Wessman Y., Almgren P., Groop L. High levels of nonesterified fatty acids are associated with increased familial risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 20:2000;1588-1594.
10. Stein D.T., Stevenson B.E., Chester M.W., et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest. 100:1997;398-403.
11. Cnop M., Hannaert J.C., Hoorens A., et al. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes. 50:2001;1771-1777.
12. Lupi R., Dotta F., Marselli L., et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated . Diabetes. 51:2002;1437-1442.
13. Listenberger L.L., Han X., Lewis S.E., et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 18:2003;3077-3082.
14. Unger R.H. The physiology of cellular liporegulation. Annu Rev Physiol. 65:2003;333-347.
15. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 103:1999;253-259.
16. Reaven G.M., Chen Y.-D.I. Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med. 85:(suppl 5A):1988;106-113.
17. Boden G., Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest. 96:1995;1261-1268.
18. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Phys. 3:1999;241-248.
19. McGarry J.D. What if Minkowski had been ageusic?. An alternative angle on diabetes. Science. 258:1992;766-770.
20. Unger R.H. Lipotoxic diseases. Annu Rev Med. 53:2002;319-336.
21. Unger R.H., Orci L. Diseases of liporegulation new perspective on obesity and related disorders . FASEB J. 15:2001;312-321.
22. Koyama K., Chen G., Lee Y., Unger R.H. Tissue triglycerides, insulin resistance, and insulin production implications for hyperinsulinemia of obesity . Am J Physiol. 273:1997;E708-E713.
23. Shimabukuro M., Higa M., Zhou Y.-T., et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats role of serine palmitoyltransferase overexpression . J Biol Chem. 273:1998;32487-32490.
24. Lee Y., Hirose H., Ohneda M., et al. β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats impairment in adipocyte-β-cell relationships . Proc Natl Acad Sci U S A. 91:1994;10878-10882.
25. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes a prospective disease . Diabetes. 44:1995;1249-1258.
26. Shimabukuro M., Zhou Y.-T., Lee Y., Unger R.H. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 273:1998;3547-3550.
27. Finegood D.T., McArthur M.D., Kojwang D., et al. β-Cell mass dynamics in Zucker diabetic fatty rats rosiglitazone prevents the rise in net cell death . Diabetes. 50:2001;1021-1029.
28. Carey D.G., Cowin G.J., Galloway G.J., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res. 10:2002;1008-1015.
29. Miyazaki Y., Glass L., Triplitt C., et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 44:2001;2210-2219.
30. Oakes N.D., Thalén P.G., Jacinto S.M., Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes. 50:2001;1158-1165.
31. Mayerson A.B., Hundal R.S., Dufour S., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
32. Miyazaki Y., Mahankali A., Matsuda M., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 87:2002;2784-2791.
33. Steinberg H.O., Chaker H., Leaming R., et al. Obesity/insulin resistance is associated with endothelial dysfunction implications for the syndrome of insulin resistance . J Clin Invest. 97:1996;2601-2610.
34. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases the role of oxidant stress . Circ Res. 87:2000;840-844.
35. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1992;1076-1083.
36. Du X.L., Edelstein D., Dimmeler S., et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 108:2001;1341-1348.
37. Arcaro G., Cretti A., Balzano S., et al. Insulin causes endothelial dysfunction in humans sites and mechanisms . Circulation. 105:2002;576-582.
38. Stepniakowski K.T., Goodfriend T.L., Egan B.M. Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension. 25:1995;774-778.
39. Paolisso G., Gambardella A., Tagliamonte M.R., et al. Does free fatty acid infusion impair insulin action also through an increase in oxidative stress? J Clin Endocrinol Metab. 81:1996;4244-4248.
40. Pleiner J., Schaller G., Mittermayer F., et al. FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab. 87:2002;2913-2917.
41. Ferrannini E., Barrett E.J., Bevilacqua S., et al. Effect of free fatty acids on blood amino acid levels in humans. Am J Physiol. 250:1986;E686-E694.
42. Davda R.K., Stepniakowski K.T., Lu G., et al. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension. 26:1995;764-770.
43. Martens F.M.A.C., Visseren F.L.J., Lemay J., et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 62:2002;1463-1480.
44. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 340:1999;14-22.
45. Law R.E., Goetze S., Xi X.-P., et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 101:2000;1311-1318.
46. Minamikawa J., Tanaka S., Yamauchi M., et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endrocrinol Metab. 83:1998;1818-1820.
47. Koshiyama H., Shimono D., Kuwamura N., et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 86:2001;3452-3456.
48. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin-dependent diabetes mellitus a serial intravascular ultrasound study . J Am Coll Cardiol. 36:2000;1529-1535.
49. Ogihara T., Rakugi H., Ikegami H., et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 8:1995;316-320.
50. Sung B.H., Izzo J.L. Jr, Dandona P., Wilson M.F. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 34:1999;83-88.
51. Fullert S., Schneider F., Haak E., et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension a double-blind, placebo-controlled study . J Clin Endocrinol Metab. 87:2002;5503-5506.
52. Bakris G., Viberti G., Weston W.M., et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 17:2003;7-12.
53. Raji A., Seely E.W., Bekins S.A., et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 26:2003;172-178.
54. Buchanan T.A., Meehan W.P., Jeng Y.Y., et al. Blood pressure lowering by pioglitazone evidence for a direct vascular effect . J Clin Invest. 96:1995;354-360.
55. Sun L., Halaihel N., Zhang W., et al. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 277:2002;18919-18927.
56. Diercks G.F.H., van Boven A.J., Hillege H.L., et al. Microalbuminuria is independently associated with ischaemic electrographic abnormalities in a large non-diabetic population the PREVEND (Prevention of REnal and Vascular ENdstage Disease) study . Eur Heart J. 21:2000;1922-1927.
57. Bakris G.L. Microalbuminuria what is it? Why is it important? What should be done about it? J Clin Hypertens. 3:2001;99-102.
58. Garg J.P., Bakris G.L. Microalbuminuria marker of vascular dysfunction, risk factor for cardiovascular disease . Vasc Med. 7:2002;35-43.
59. Alberti K.G.M.M., Zimmet P.Z. Definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:1998;539-553.
60. Nakamura T., Ushiyama C., Shimada N., et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 14:2000;250-254.
61. Nakamura T., Ushiyama C., Osada S., et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 50:2001;1193-1196.
62. Nozue T., Michishita I., Minagawa F., Genda A. Troglitazone directly increases HDL cholesterol levels. Diabetes Care. 22:1999;355-356.
63. Tack C.J.J., Smits P., Demacker P.N.M., Stalenhoef A.F.H. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 21:1998;796-799.
64. Freed M.I., Ratner R., Marcovina S.M., et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 90:2002;947-952.
65. Boyle P.J., King A.B., Olansky L., et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus a retrospective review of randomly selected medical records . Clin Ther. 24:2002;378-396.
66. Baba S. Pioglitazone a review of Japanese clinical studies . Curr Med Res Opin. 17:2001;166-189.
67. Rosenblatt S., Miskin B., Glazer N.B., et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 12:2001;413-423.
68. Hirose H., Kawai T., Yamamoto Y., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 51:2002;314-317.
69. Einhorn D., Rendell M., Rosenzweig J., et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus a randomized, placebo-controlled study . Clin Ther. 22:2000;1395-1409.
70. Kipnes M.S., Krosnick A., Rendell M.S., et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus a randomized, placebo-controlled study . Am J Med. 111:2001;10-17.
71. Jun J.K., Gong W.C., Mathur R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm. 60:2003;469-473.
72. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
73. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
74. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Circulation. 1997;95:69-75.
75. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002;160:41-48.
76. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
77. Marals AD. Therapeutic modulation of low-density lipoprotein size. Curr Opin Lipidol. 2000;11:597-602.